Mr. Hugin
PersonRelationship Network
Event Timeline
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
Celgene
|
Executive company |
7
|
1 | |
|
person
Celgene
|
Employment |
7
|
1 | |
|
person
Mr. Menendez
|
Unknown |
6
|
1 | |
|
person
Celgene
|
Employee |
5
|
1 | |
|
person
Mr. Menendez
|
Political opponents |
5
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | Mr. Hugin, a managing director at J.P. Morgan, was hired by Celgene as a top executive. | N/A | View |
| 2004-01-01 | N/A | Mr. Hugin spoke at an investor conference, calling Thalomid the company's 'financial engine'. | N/A | View |
| 1999-06-01 | N/A | Mr. Hugin arrived at Celgene while the company was struggling to profit from its only drug, Thalo... | New Jersey | View |
| 1999-01-01 | N/A | Mr. Hugin arrived at Celgene, which was struggling to profit from its only marketed drug, Thalomid. | New Jersey | View |
HOUSE_OVERSIGHT_028421.jpg
This document contains text segments describing the pharmaceutical company Celgene, its former executive Mr. Hugin, and its practice of raising drug prices. Specifically, it details price hikes for the drug Revlimid, the financial impact on the company, and the human cost as exemplified by a patient, Elaine Kodish. The text also includes commentary from a financial analyst and mentions a political campaign leveraging the issue.
HOUSE_OVERSIGHT_028419.jpg
This document, from a House Oversight file, details the business practices of the pharmaceutical company Celgene concerning its drugs Thalomid and Revlimid between 2000 and 2017. It outlines allegations of improper 'off-label' marketing, significant price increases, and aggressive strategies to extend its patent monopoly and block competition from generic drug makers. The document includes quotes from a Celgene executive, a federal regulatory agency, and a generic drug industry representative.
HOUSE_OVERSIGHT_028418.jpg
This document is a digital article, labeled for a House Oversight investigation, concerning the pharmaceutical company Celgene and its executive, Mr. Hugin. It details the company's aggressive marketing of the drug Thalomid for unapproved uses shortly after its launch, leading to multiple reprimands from the F.D.A. in the late 1990s and a whistle-blower lawsuit settled in 2017. The document is not related to Jeffrey Epstein.
HOUSE_OVERSIGHT_028417.jpg
This document is a data extract, likely from a news article, which has been marked as an exhibit for a House Oversight investigation. The text details the history of the pharmaceutical company Celgene and its drug Thalomid (thalidomide), including its approval by the F.D.A. in 1998 and the context of executive Bob Hugin's subsequent political career. The document contains no information related to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_028416.jpg
This document is an excerpt from an article detailing controversies surrounding pharmaceutical executive Mr. Hugin, a former CEO of Celgene. It highlights Celgene's aggressive drug promotion, a $280 million settlement for illegal marketing, and accusations of fighting generic competition. The text notes that these issues, particularly rising drug costs, are being used against Hugin in a political campaign by his opponent, Mr. Menendez.
Investor Conference
At an investor conference, Mr. Hugin stated, "Thalomid is important, because it is the financial engine that drives us."
Investor Conference
At an investor conference, Mr. Hugin stated, "Thalomid is important, because it is the financial engine that drives us."
Investor Conference
At an investor conference, Mr. Hugin stated, "Thalomid is important, because it is the financial engine that drives us."
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity